Is there a Need to Rush to Treatment when you Experience a Biochemical (PSA only) Prostate Cancer Recurrence?
As usual, we are confronted with a new contradiction. It has been believed that earl hormone therapy (ADT) in men with a biochemical recurrence (PSA only) would benefit from immediate ADT. A study released from [...]
Does Prior Response to Zytiga Affect Subsequent Activity of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)?
Given all the newly approved drugs available to us to treat advanced prostate cancer there now are many questions about the optimal sequencing of these drugs and whether earlier use of one causes cross-resistance to [...]
Which Men are at the Greatest Risk of Weight Gain on Hormone Therapy? Knowing Your Risk Factors
Androgen deprivation therapy (ADT) is the most common first therapy for men diagnosed with metastatic prostate cancer as well as many men with non-metastatic prostate cancer. ADT brings with it many side effects including significant [...]
Preliminary Data Released for A Phase II Trial of Sipuleucel-T (Provenge) with Concurrent or Sequential Enzalutamide (Xtandi) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
There will be an abstract presented at the Upcoming (May 31- June 3) American Society of Clinical Oncologist Annual Meeting (ASCO) providing very preliminary data on a clinical trial combing Sipuleucel-T (Provenge) and enzalutamide (Xtandi) [...]
Startling Fact: PSA Testing Frequency Changes PSA Doubling Time – A Time Honored Surrogate Biomarker is Not Valid!
In our quest to understand our prostate cancer we have developed many “measures” of our disease aggressiveness and progression. Many of these measures are generally accepted has valid, but many have never been validated. One [...]
NICE Rejects Zytiga for Men Without Chemotherapy Exposure
The National Institute for Health and Care Excellence (NICE), which is Britain’s healthcare cost-effectiveness agency, has determined that abiraterone (Zytiga) was not worth giving to men with castrate resistant metastatic prostate cancer who have yet [...]